Index removals put Addus HomeCare in focus

Addus HomeCare (ADUS) has dropped out of several Russell growth and small cap benchmarks, an event that can prompt passive fund selling and lead investors to reassess how they view the stock.

Despite the index removals, Addus HomeCare’s recent trading has been firm, with a 7.83% 7 day share price return and a 14.80% 30 day share price return. The 1 year total shareholder return has declined 4.42% but remains positive over 3 and 5 years.

If this kind of re rating has you looking beyond a single stock, it could be a good moment to widen your search using our screener for 40 healthcare AI stocks

The recent rally in Addus HomeCare after its Russell exits leaves a wide gap between the US$105.73 share price, analyst targets near US$132.69 and some intrinsic value estimates. Where does fair value really sit within that spread?

Most Popular Narrative: 4.8% Overvalued

The most followed narrative for Addus HomeCare pegs fair value at $100.85 using a 7.11% discount rate, slightly below the recent $105.73 share price.

The looming threat of significant government healthcare spending cuts to address federal budget deficits could reduce funding for Medicaid and Medicare programs, which are critical revenue streams for Addus HomeCare; this would directly pressure revenue and earnings, especially as provisions of the reconciliation bill begin to impact state budgets in 2028.

Persistent and escalating labor costs, including wage increases mandated by state policies and ongoing caregiver shortages, are likely to compress net margins; despite recent hiring success, the long-term demographic shift and intensified competition for caregivers may lead to higher recruitment and retention costs, lowering profitability over time.

Curious how this narrative still arrives at a higher earnings base and firmer margins over time, even with these pressures in the background? The entire framework relies on a steady revenue build, slightly stronger profitability and a future earnings multiple that is more conservative than many peers. The real interest is in how those three levers are combined to justify fair value.

Result: Fair Value of $100.85 (OVERVALUED)

However, if state reimbursement trends remain supportive or acquisitions continue to add EBITDA, the cautious Addus HomeCare narrative could be challenged more quickly than expected.

Another View: Multiples Paint a Different Picture for Addus HomeCare

Set against the bearish fair value narrative of $100.85, Addus HomeCare looks very different when you look at simple market pricing. The stock trades on a P/E of 19.4x, compared with 25.9x for the wider US Healthcare industry and 56.8x for its peer group, while the fair ratio sits at 20.6x.

That mix points to a company priced below both peers and the fair ratio, which can either signal a margin of safety or reflect concerns that the market believes are not fully captured in analyst models. The question for investors is whether this discount is a warning sign or an opening worth investigating further.

Next Steps

If the back and forth on Addus HomeCare leaves you unsure, it may be helpful to move quickly and evaluate the positives for yourself. A good place to start is the 5 key rewards.

Looking for more Addus HomeCare investment ideas?

Before you move on from Addus HomeCare, take a few minutes to scan other stocks that could suit your goals so you are not relying on a single story.

• Spot opportunities with strong cash generation and appealing valuations by reviewing companies in the 41 high quality undervalued stocks.
• Prioritize stability and capital preservation by checking out stocks in the 74 resilient stocks with low risk scores.
• Hunt for underfollowed opportunities with solid fundamentals using the screener containing 18 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.